Burford Brothers Inc. Sells 8,183 Shares of Johnson & Johnson $JNJ

Burford Brothers Inc. cut its holdings in Johnson & Johnson (NYSE:JNJ) by 47.7% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 8,979 shares of the company’s stock after selling 8,183 shares during the period. Burford Brothers Inc.’s holdings in Johnson & Johnson were worth $1,372,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of JNJ. Wealthstream Advisors Inc. increased its holdings in shares of Johnson & Johnson by 3.4% in the second quarter. Wealthstream Advisors Inc. now owns 2,101 shares of the company’s stock worth $321,000 after buying an additional 70 shares during the period. SAM Advisors LLC grew its position in Johnson & Johnson by 3.0% during the 2nd quarter. SAM Advisors LLC now owns 12,172 shares of the company’s stock worth $1,859,000 after acquiring an additional 359 shares during the last quarter. Gladwyn Financial Advisors Inc. purchased a new position in Johnson & Johnson in the 2nd quarter worth approximately $71,000. Schubert & Co lifted its position in Johnson & Johnson by 5.8% in the second quarter. Schubert & Co now owns 2,144 shares of the company’s stock valued at $328,000 after purchasing an additional 117 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $157,608,000. 69.55% of the stock is owned by institutional investors.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $193.27 on Monday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a one year low of $140.68 and a one year high of $194.40. The company has a 50-day simple moving average of $180.49 and a two-hundred day simple moving average of $164.90. The firm has a market capitalization of $465.45 billion, a PE ratio of 18.65, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%. On average, analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Analyst Upgrades and Downgrades

Several research analysts recently commented on JNJ shares. Barclays lifted their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. The Goldman Sachs Group upped their price objective on shares of Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a research note on Thursday, October 9th. Guggenheim upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their target price for the stock from $167.00 to $206.00 in a report on Tuesday, September 23rd. Royal Bank Of Canada restated an “outperform” rating and set a $209.00 price target on shares of Johnson & Johnson in a report on Friday, October 10th. Finally, HSBC increased their price objective on Johnson & Johnson from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $199.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.